NeuroMetrix Rceives GSK 'Bridge' For Quell Wearable Pain-Relief Development

Recent modifications accelerated portion of milestones remaining in firms' agreement over the next 12 months, reduced GSK's aggregate amount payable and forwarded $2m to NeuroMetrix. Firms are co-funding future development of Quell technology and additional TENS products for chronic pain beginning in 2019.

NeuroMetrix Inc. has received a $2m advance from GlaxoSmithKline PLC in a modification of the firms' agreement for GSK to provide up to $13.8m funding for development and commercialization of NeuroMetrix' Quell wearable pain-relief technology.

The modifications announced Dec. 11 accelerated a portion of milestones remaining in the firms' agreement over the next 12 months...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Business

Over The Counter: Seizing The GLP-1 Wellness Opportunity, With Kerry Group’s Mathieu Millette

 
• By 

HBW Insight speaks to Kerry Group's RDA director for digestive health, Mathieu Millette, about the opportunity represented by the global trend for GLP-1 agonists for consumer health.

Consumers More Often Choosing Private Label First

 

First Insight report from survey conducted in April with 1,267 US consumers notes that the Private Label Manufacturers Association recorded private label sales increasing by nearly 4% in 2024 to a record $271bn.

People In US Consumer Health News: Bayer North America Treasurer Takes On CFO Role, Too

 

Bayer North America CFO with firm since 2008; Cosette VP for quality, regulatory affairs; FDA labeling review official joins ProPharma; Lifecykel, UFC veterans launch Mongolian training camp; and Beverly Hills surgeons offer skin care supplement.

OLLY’s Lovin’ Libido Claims Score Support With Studies Of Women Reporting ‘Generally Low’ Desire

 

NAD reports the populations of six of seven RCTs Olly referenced as evidence were key in substantiating claims for Lovin’ Libido ashwagandha supplement challenged by Bayer. Supplement industry, though, is challenging the FTC’s RCT standard for claims support.

More from Wellness

OLLY’s Lovin’ Libido Claims Score Support With Studies Of Women Reporting ‘Generally Low’ Desire

 

NAD reports the populations of six of seven RCTs Olly referenced as evidence were key in substantiating claims for Lovin’ Libido ashwagandha supplement challenged by Bayer. Supplement industry, though, is challenging the FTC’s RCT standard for claims support.

Cloudy Tariff Conditions Expected To Linger In US

 

White House announces president extends deadline he set in April for other countries to make new tariff deals from July 9 to Aug. 1, when the administration will start sending letters warning other countries that higher tariffs could take effect.

US FDA’s Tough Talk On Talc: Regulating In An Echo Chamber

 

An FDA “expert roundtable” on talc produced a new talking point on a potential drug safety risk, but the basis of that claim is difficult to determine.